Seminars in Nephrology
Volume 27, Issue 5 , Pages 544-554 , September 2007

Rationale for Combining Blockers of the Renin-Angiotensin System

  • Michel Azizi, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Michel Azizi, MD, PhD, Clinical Investigation Center 9201, Hôpital Européen Georges Pompidou, 20-40 Rue Leblanc, 75908 Paris, Cedex 15, France.
    • ,
  • Grégoire Wuerzner, MD

References 

  1. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492–2499
  2. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  3. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46
  4. Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ. 1988;297:1092–1095
  5. Flather MD, Yusuf S, Kober L, et al. ACE-Inhibitor Myocardial Infarction Collaborative Group Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581
  6. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  7. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906
  8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691
  9. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97:2202–2212
  10. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial (Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan). Lancet. 2002;360:752–760
  11. Lewis EJ, Hunsicker LG, Bain RP, et al. The Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462
  12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  14. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863
  15. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  16. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728
  17. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (A meta-analysis of patient-level data). Ann Intern Med. 2001;135:73–87
  18. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (The Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:145–153
  19. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  20. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581–588
  21. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068
  22. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261–271
  23. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803
  24. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 1990;16:363–370
  25. Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem-cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. J Clin Invest. 1996;97:839–844
  26. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35:155–163
  27. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348–22357
  28. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2:277–284
  29. Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004;15:166–169
  30. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res. 2006;98:463–471
  31. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology (XXIII. The angiotensin II receptors). Pharmacol Rev. 2000;52:415–472
  32. Nguyen G, Delarue F, Berrou J, et al. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 1996;50:1897–1903
  33. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417–1427
  34. Gavras H, Biollaz J, Waeber B, et al. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor “MK-421”. Lancet. 1981;2:543–547
  35. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–1052
  36. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens. 2006;24:243–256
  37. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387–392
  38. Richard V, Hurel-Merle S, Scalbert E, et al. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation. 2001;104:750–752
  39. Saris JJ, van Dijk MA, Kroon I, et al. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension. 2000;35:764–768
  40. Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699–705
  41. Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25–49
  42. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838–854
  43. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation. 2006;114:855–860
  44. Iwamoto N, Xano HJ, Yoshioka T, et al. Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci. 2000;66:PL221–PL226
  45. Kanasaki K, Haneda M, Sugimoto T, et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators. Biochem Biophys Res Commun. 2006;342:758–765
  46. Rhaleb NE, Peng H, Harding P, et al. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension. 2001;37:827–832
  47. Peng H, Carretero OA, Raij L, et al. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension. 2001;37:794–800
  48. Rhaleb NE, Peng H, Yang XP, et al. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation. 2001;103:3136–3141
  49. Pokharel S, Rasoul S, Roks AJ, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension. 2002;40:155–161
  50. Pokharel S, van Geel PP, Sharma UC, et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation. 2004;110:3129–3135
  51. Kanasaki K, Koya D, Sugimoto T, et al. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol. 2003;14:863–872
  52. Shibuya K, Kanasaki K, Isono M, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes. 2005;54:838–845
  53. Omata M, Taniguchi H, Koya D, et al. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J Am Soc Nephrol. 2006;17:674–685
  54. de Gasparo M, Cumin F, Nussberger J, et al. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol. 1989;27:587–596
  55. van den Meiracker AH, Admiraal PJ, Man in’t Veld AJ, et al. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. BMJ. 1990;301:205–210
  56. MacFadyen RJ, Jones CR, Doig JK, et al. Responses to an orally active renin inhibitor, remikiren (Ro 425892), after controlled salt depletion in humans. J Cardiovasc Pharmacol. 195;25:347-53.
  57. Menard J, Boger RS, Moyse DM, et al. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation. 1995;91:330–338
  58. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities?. J Am Soc Nephrol. 2005;16:592–599
  59. Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7:493–504
  60. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705
  61. Derkx FH, Deinum J, Lipovski M, et al. Nonproteolytic “activation” of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. J Biol Chem. 1992;267:22837–22842
  62. Menard J, Guyene TT, Peyrard S, et al. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens. 2006;24:529–534
  63. Stubbs AJ, Skinner SL. Lectin chromatography of extrarenal renin protein in human plasma and tissues: potential endocrine function via the renin receptor. J Renin Angiotensin Aldosterone Syst. 200;5:189-96.
  64. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005;46:1069–1076
  65. van Kesteren CA, Danser AH, Derkx FH, et al. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension. 1997;30:1389–1396
  66. Luetscher JA, Kraemer FB, Wilson DM, et al. Increased plasma inactive renin in diabetes mellitus (A marker of microvascular complications). N Engl J Med. 1985;312:1412–1417
  67. Veniant M, Menard J, Bruneval P, et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1966–1970
  68. Fisher ND, Allan DR, Gaboury CL, et al. Intrarenal angiotensin II formation in humans (Evidence from renin inhibition). Hypertension. 1995;25:935–939
  69. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10:2382–2391
  70. Aviv A, Hollenberg NK, Weder AB. Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans. Kidney Int. 2004;65:361–368
  71. van Paassen P, de Zeeuw D, de Jong PE, et al. Renin inhibition improves pressure natriuresis in essential hypertension. J Am Soc Nephrol. 200;11:1813-8.
  72. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–124
  73. Packer M, Poole-Wilson PA, Armstrong PW, et al. ATLAS Study Group Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–2318
  74. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328:495
  75. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000;355:253–259
  76. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041
  77. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  78. Juillerat L, Nussberger J, Ménard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564–572
  79. Maillard MP, Wurzner G, Nussberger J, et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther. 2002;71:68–76
  80. Van Den Meiracker AH, Man in’t veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?. J Hypertens. 1992;10:803–812
  81. Lees KR. The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens. 1992;10:S3–S11
  82. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers (Differences in potency and efficacy). Blood Press. 2002;11:293–301
  83. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart. 1999;82:57–61
  84. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844–846
  85. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable?. J Am Coll Cardiol. 2001;37:1456–1460
  86. Vos PF, Boer P, Braam B, et al. Efficacy of intrarenal ACE-inhibition estimated from the renal response to angiotensin I and II in humans. Kidney Int. 1995;47:274–281
  87. Campbell DJ. Differential regulation of angiotensin peptides in plasma and kidney: effects of adrenalectomy and estrogen treatment. Clin Exp Hypertens. 1997;19:687–698
  88. Nussberger J. Circulating versus tissue angiotensin II. In:  Epstein M,  Brunner HR editor. Angiotensin II receptor antagonists. Philadelphia: Hanley and Belfus Inc; 2000;p. 69–78
  89. Grima M, Ingert C, Michel B, et al. Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat. Clin Exp Hypertens. 1997;19:671–685
  90. Navar LG, Harrison-Bernard LM, Nishiyama A, et al. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002;39:316–322
  91. Vane JR. Sites of conversion of angiotensin I. In:  Genest J,  Koiw E editor. Hypertension 72. Berlin: Springer-Verlag; 1972;p. 523–532
  92. Navar GL, Mitchell KD, Harrison-Bernard LM, et al. Intrarenal angiotensin II levels in normal and hypertensive states. J Renin Angiotensin Aldosterone Syst. 2001;2:S176–S184
  93. van Kats JP, Schalekamp MA, Verdouw PD, et al. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int. 2001;60:2311–2317
  94. Ikoma M, Kawamura T, Kakinuma Y, et al. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int. 1991;40:195–202
  95. Wollert KC, Studer R, von Bulow B, et al. Survival after myocardial infarction in the rat (Role of tissue angiotensin-converting enzyme inhibition). Circulation. 1994;90:2457–2467
  96. Chobanian AV, Haudenschild CC, Nickerson C, et al. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992;20:473–477
  97. Rakugi H, Wang DS, Dzau VJ, et al. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation. 1994;90:449–455
  98. Chobanian AV, Hope S, Brecher P. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1995;25:1306–1310
  99. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919–925
  100. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  101. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771
  102. Morgan T, Griffiths C, Delbridge L. Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive. Am J Hypertens. 2002;15:1003–1005
  103. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564–572
  104. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?. Hypertension. 2003;41:31–36
  105. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190–1198
  106. Schmieder RE, Klingbeil AU, Fleischmann EH, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038–3045
  107. Morgan T, Anderson A, Bertram D, et al. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst. 2004;5:64–71
  108. Azizi M, Bissery A, Bura-Riviere A, et al. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens. 2003;21:1887–1895
  109. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–3133
  110. Wood JM, Schnell CR, Cumin F, et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417–426
  111. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20
  112. Oparil S, Yarows SA, Patel A, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–229
  113. Sleight P. The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol. 2005;42(Suppl 1):S50–S56

 Supported in part by the Association Naturalia et Biologia and the Association Robert Debré.

PII: S0270-9295(07)00087-3

doi: 10.1016/j.semnephrol.2007.07.002

Seminars in Nephrology
Volume 27, Issue 5 , Pages 544-554 , September 2007

Article Tools